Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

ClinicalTrials.gov ID: NCT04996797

Public ClinicalTrials.gov record NCT04996797. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 12:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis

Study identification

NCT ID
NCT04996797
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Enrollment
178 participants

Conditions and interventions

Interventions

  • Tulisokibart Drug
  • Companion Diagnostic (CDx) Testing Device
  • Placebo Other

Drug · Device · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 13, 2021
Primary completion
Jun 5, 2023
Completion
Jul 13, 2025
Last update posted
Aug 5, 2025

2021 – 2025

United States locations

U.S. sites
29
U.S. states
17
U.S. cities
27
Facility City State ZIP Site status
Prometheus Biosciences Selected Center Mobile Alabama 36608
Prometheus Biosciences Selected Site Phoenix Arizona 85006
Prometheus Biosciences Selected Site Sun City Arizona 85351
Prometheus Biosciences Selected Site Los Angeles California 90045
Prometheus Biosciences Selected Site Los Angeles California 90048
Prometheus Biosciences Selected Site San Diego California 92037
Prometheus Biosciences Selected Site Bristol Connecticut 06010
Prometheus Biosciences Selected Site Atlanta Georgia 30010
Prometheus Biosciences Selected Site Arlington Heights Illinois 60005
Prometheus Biosciences Selected Site Glenview Illinois 60026
Prometheus Biosciences Selected Site Gurnee Illinois 60031
Prometheus Biosciences Selected Site Kansas City Kansas 66160
Prometheus Biosciences Selected Site Liberty Kansas 64098
Prometheus Biosciences Selected Site Baton Rouge Louisiana 70809
Prometheus Biosciences Selected Site Chevy Chase Maryland 20815
Prometheus Biosciences Selected Site Chesterfield Michigan 48047
Prometheus Biosciences Selected Site Lebanon New Hampshire 03756
Prometheus Biosciences Selected Site New York New York 10029
Prometheus Biosciences Selected Site New York New York 10065
Prometheus Biosciences Selected Site Dublin Ohio 43016
Prometheus Biosciences Selected Site Germantown Tennessee 38138
Prometheus Biosciences Selected Site Bedford Texas 76022
Prometheus Biosciences Selected Site Lubbock Texas 79424
Prometheus Biosciences Selected Site Mansfield Texas 76063
Prometheus Biosciences Selected Site San Antonio Texas 78229
Prometheus Biosciences Selected Site Southlake Texas 76092
Prometheus Biosciences Selected Site Tyler Texas 75702
Prometheus Biosciences Selected Site Charlottesville Virginia 22903
Prometheus Biosciences Selected Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04996797, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 5, 2025 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04996797 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →